Results of Dual Interphase FISH Performed in Patients No. 11, 12, 15, and 17, Both at Diagnosis [a] and at Follow-Up [b]
| Patient No. . | 11 a (%) . | 11 b (%) . | 12 a (%) . | 12 b (%) . | 15 a (%) . | 15 b (%) . | 17 a (%) . | 17 b (%) . |
|---|---|---|---|---|---|---|---|---|
| Testing probes for chr no. 3 and no. 7: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 7 | 24 | 26 | 15 | 8 | 34 | 21 | ||
| 3 sign. no. 3 + 2 sign. no. 7 | 19 | 27 | 12 | 18 | 16 | 15 | ||
| 2 sign. no. 3 + 3 sign. no. 7 | 10 | 12 | 10 | |||||
| 3 sign. no. 3 + 3 sign. no. 7 | 49 | 29 | 56 | 58 | 30 | 48 | ||
| 4 sign. no. 3 + 3 sign. no. 7 | 6 | |||||||
| 3 sign. no. 3 + 4 sign. no. 7 | 5 | |||||||
| Testing probes for chr no. 3 and no. 9: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 9 | 9 | 24 | 18 | 25 | 10 | 19 | 30 | 8 |
| 3 sign. no. 3 + 2 sign. no. 9 | 29 | 40 | 35 | 29 | 19 | 20 | 23 | 19 |
| 2 sign. no. 3 + 3 sign. no. 9 | 18 | |||||||
| 3 sign. no. 3 + 3 sign. no. 9 | 47 | 33 | 40 | 33 | 59 | 47 | 29 | 44 |
| 4 sign. no. 3 + 3 sign. no. 9 | 4 | 16 | ||||||
| Testing probes for chr no. 3 and no. 11: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 11 | 14 | 24 | ||||||
| 3 sign. no. 3 + 2 sign. no. 11 | 19 | 33 | ||||||
| 3 sign. no. 3 + 3 sign. no. 11 | 60 | 39 | ||||||
| Testing probes for chr no. 7 and no. 9: | ||||||||
| 2 sign. no. 7 + 2 sign. no. 9 | 31 | 30 | 16 | 15 | 56 | 20 | ||
| 3 sign. no. 7 + 2 sign. no. 9 | 23 | 24 | 11 | 15 | 11 | |||
| 2 sign. no. 7 + 3 sign. no. 9 | 12 | 14 | 17 | 15 | 17 | 23 | ||
| 3 sign. no. 7 + 3 sign. no. 9 | 31 | 32 | 46 | 42 | 16 | 28 | ||
| 3 sign. no. 7 + 4 sign. no. 9 | 5 | 3 | ||||||
| 4 sign. no. 7 + 3 sign. no. 9 | 7 | |||||||
| Testing probes for chr no. 7 and no. 11: | ||||||||
| 2 sign. no. 7 + 2 sign. no. 11 | 40 | 38 | 45 | 22 | ||||
| 3 sign. no. 7 + 2 sign. no. 11 | 12 | |||||||
| 2 sign. no. 7 + 3 sign. no. 11 | 56 | 48 | 16 | 17 | ||||
| 3 sign. no. 7 + 3 sign. no. 11 | 18 | 47 | ||||||
| Testing probes for chr no. 9 and no. 11: | ||||||||
| 2 sign. no. 9 + 2 sign. no. 11 | 17 | 23 | 50 | 23 | 20 | |||
| 3 sign. no. 9 + 2 sign. no. 11 | 17 | 22 | 39 | 18 | 13 | |||
| 2 sign. no. 9 + 3 sign. no. 11 | 10 | 12 | 27 | 28 | ||||
| 3 sign. no. 9 + 3 sign. no. 11 | 36 | 36 | 27 | 33 | ||||
| 4 sign. no. 9 + 2 sign. no. 11 | 7 | |||||||
| 4 sign. no. 9 + 3 sign. no. 11 | 11 | 5 |
| Patient No. . | 11 a (%) . | 11 b (%) . | 12 a (%) . | 12 b (%) . | 15 a (%) . | 15 b (%) . | 17 a (%) . | 17 b (%) . |
|---|---|---|---|---|---|---|---|---|
| Testing probes for chr no. 3 and no. 7: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 7 | 24 | 26 | 15 | 8 | 34 | 21 | ||
| 3 sign. no. 3 + 2 sign. no. 7 | 19 | 27 | 12 | 18 | 16 | 15 | ||
| 2 sign. no. 3 + 3 sign. no. 7 | 10 | 12 | 10 | |||||
| 3 sign. no. 3 + 3 sign. no. 7 | 49 | 29 | 56 | 58 | 30 | 48 | ||
| 4 sign. no. 3 + 3 sign. no. 7 | 6 | |||||||
| 3 sign. no. 3 + 4 sign. no. 7 | 5 | |||||||
| Testing probes for chr no. 3 and no. 9: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 9 | 9 | 24 | 18 | 25 | 10 | 19 | 30 | 8 |
| 3 sign. no. 3 + 2 sign. no. 9 | 29 | 40 | 35 | 29 | 19 | 20 | 23 | 19 |
| 2 sign. no. 3 + 3 sign. no. 9 | 18 | |||||||
| 3 sign. no. 3 + 3 sign. no. 9 | 47 | 33 | 40 | 33 | 59 | 47 | 29 | 44 |
| 4 sign. no. 3 + 3 sign. no. 9 | 4 | 16 | ||||||
| Testing probes for chr no. 3 and no. 11: | ||||||||
| 2 sign. no. 3 + 2 sign. no. 11 | 14 | 24 | ||||||
| 3 sign. no. 3 + 2 sign. no. 11 | 19 | 33 | ||||||
| 3 sign. no. 3 + 3 sign. no. 11 | 60 | 39 | ||||||
| Testing probes for chr no. 7 and no. 9: | ||||||||
| 2 sign. no. 7 + 2 sign. no. 9 | 31 | 30 | 16 | 15 | 56 | 20 | ||
| 3 sign. no. 7 + 2 sign. no. 9 | 23 | 24 | 11 | 15 | 11 | |||
| 2 sign. no. 7 + 3 sign. no. 9 | 12 | 14 | 17 | 15 | 17 | 23 | ||
| 3 sign. no. 7 + 3 sign. no. 9 | 31 | 32 | 46 | 42 | 16 | 28 | ||
| 3 sign. no. 7 + 4 sign. no. 9 | 5 | 3 | ||||||
| 4 sign. no. 7 + 3 sign. no. 9 | 7 | |||||||
| Testing probes for chr no. 7 and no. 11: | ||||||||
| 2 sign. no. 7 + 2 sign. no. 11 | 40 | 38 | 45 | 22 | ||||
| 3 sign. no. 7 + 2 sign. no. 11 | 12 | |||||||
| 2 sign. no. 7 + 3 sign. no. 11 | 56 | 48 | 16 | 17 | ||||
| 3 sign. no. 7 + 3 sign. no. 11 | 18 | 47 | ||||||
| Testing probes for chr no. 9 and no. 11: | ||||||||
| 2 sign. no. 9 + 2 sign. no. 11 | 17 | 23 | 50 | 23 | 20 | |||
| 3 sign. no. 9 + 2 sign. no. 11 | 17 | 22 | 39 | 18 | 13 | |||
| 2 sign. no. 9 + 3 sign. no. 11 | 10 | 12 | 27 | 28 | ||||
| 3 sign. no. 9 + 3 sign. no. 11 | 36 | 36 | 27 | 33 | ||||
| 4 sign. no. 9 + 2 sign. no. 11 | 7 | |||||||
| 4 sign. no. 9 + 3 sign. no. 11 | 11 | 5 |
After hybridization with every couple of probes, each plasma cell showed a variable number of red and green signals (2, 3, or 4 signals with each fluorescence). Ninety-one to 165 PC were enumerated on each slide, and data were converted next in % and reported in the table (only data over the thresholds [see text] are reported). In each patient, chromosomic numeric changes are distributed in several different patterns. These patterns correspond to subpopulations of plasma cells showing disomy, trisomy, or even tetrasomy for one chromosome tested and either disomy, trisomy, or tetrasomy for the other one chromosome tested, in each couple of probes used in the study.